HTuO Biosciences
HTuO Biosciences is a Vancouver-based deep-tech company building physics-based simulation tools that model drug-molecule interactions at the atomic level, serving pharmaceutical partners pursuing challenging and previously inaccessible therapeutic targets.
- Company typePrivate
- Founded2023
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What HTuO Biosciences does
HTuO Biosciences is a Vancouver-based private deep-technology company developing physics-based computational simulation tools for drug discovery. The company's platform applies advanced physics models to simulate drug-molecule interactions at the atomic level, positioning itself to deliver insights into drug mechanisms that the company states surpass conventional in-silico methods, including addressing targets often described as 'undruggable.'
The company's core product is a physics-based simulation platform used both for internal drug discovery and through collaborative programs with external partners. The technology is being applied to challenging therapeutic targets and novel modalities, with use cases spanning both small-molecule discovery and the exploration of previously inaccessible mechanisms. HTuO maintains an active research presence through conference poster presentations (ACS Spring 2026) and ongoing platform development led by a PhD-credentialed scientific team.
HTuO operates on a partnership-based business model, engaging directly with pharmaceutical companies through industry events (BIO International Convention, Sweet Biopharma Day, ACS), partnering portals, and direct outreach. Pricing is not publicly disclosed and the company has not announced named enterprise customers. Revenue mechanics appear to rely on collaborative drug discovery agreements with pharma partners, supplemented by early-stage grant and angel financing (cumulative disclosed funding approximately $2.5M across 2020-2025). The company has not announced APIs, software products with public distribution, or mobile applications, indicating the offering is delivered through bespoke engagements rather than self-service channels.
HTuO Biosciences firmographics
Firmographics- Name
- HTuO Biosciences
- Legal name
- HTuO Biosciences Inc.
- Website
- https://htuobio.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HTuO Biosciences is a Vancouver-based deep-tech company building physics-based simulation tools that model drug-molecule interactions at the atomic level, serving pharmaceutical partners pursuing challenging and previously inaccessible therapeutic targets.
- Ownership category
- akta.pro rank
HTuO Biosciences industry classification
Industry- Product category
- Computational Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where HTuO Biosciences is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
HTuO Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
HTuO Biosciences product offering
Product offeringCore offering
HTuO Biosciences develops and provides a proprietary physics-based simulation platform that models drug-molecule interactions at the atomic level to predict drug mechanisms and therapeutic potential. The platform is offered to pharmaceutical partners through collaborative drug discovery partnerships, enabling access to targets and modalities that conventional in-silico methods cannot address.
Product overview
HTuO Biosciences offers a physics-based simulation technology platform designed for drug discovery applications. The company's core technology leverages advanced physics models to simulate molecular interactions and drug mechanisms at the atomic level. HTuO's platform is positioned to unlock 'undruggable' targets that traditional in-silico drug design methods cannot address. The company provides its simulation technology both for internal drug discovery programs and through partnerships with external collaborators in the pharmaceutical industry.
Differentiator
Problem solved
Functional benefit
Products and services
- Physics-Based Simulation Technology Advanced physics-based simulation platform that models drug-molecule interactions at the atomic level, providing high-accuracy predictions of drug mechanisms and therapeutic potential. Delivered through collaborative drug discovery partnerships to pharmaceutical companies seeking to address targets and modalities that conventional in-silico drug design cannot resolve.
Companies that use HTuO Biosciences
Customer profileSegments1 record
Ideal customer profiles1 record
HTuO Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
HTuO Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Pharmaceutical Partners (unspecified)coreHTuO Biosciences partners with pharmaceutical companies to leverage their advanced physics simulation technology for collaborative drug discovery programs. The company pursues 'groundbreaking therapeutic strategies' alongside partners, targeting previously inaccessible therapeutic targets.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
HTuO Biosciences competitors and assessment
Company assessmentDirect peers
- Schrödinger: Schrödinger operates a leading physics-based computational platform for drug discovery and materials science, directly competing with HTuO in atomic-level simulation services for pharmaceutical partners.
- Atomwise: Atomwise applies AI/ML models to small-molecule drug discovery through pharma partnerships, overlapping with HTuO's computational, partnership-driven approach to addressing previously inaccessible targets.
- XtalPi: XtalPi combines physics-based simulations with AI to enable small-molecule and drug discovery collaborations with global pharma, mirroring HTuO's atomic-level simulation value proposition.
Broad incumbents
- Recursion Pharmaceuticals: Recursion is a scaled AI-driven drug discovery platform combining high-throughput biology with computational models, pursuing pharma partnerships and an internal pipeline similar in spirit to HTuO's offering.
- Exscientia: Exscientia partners with pharma to apply AI-driven drug design across multiple modalities, providing a comparable partnership-first, computation-led business model adjacent to HTuO's approach.
- Insitro: Insitro integrates ML with high-throughput biology to support pharma partnerships and an internal pipeline, representing a broader, better-capitalized peer in the same partnership-driven computational discovery category.
- Isomorphic Labs: Isomorphic Labs (Alphabet-backed) applies AI and physics-based modeling to drug discovery via pharma partnerships, positioning it as a well-capitalized adjacent competitor in the same computational discovery arena.
Emerging players
- Cyclica: Cyclica is a Toronto-based computational biology company using AI and biophysics for drug discovery, sharing HTuO's combination of physics modeling and pharma partnership go-to-market.
- Cresset: Cresset offers computational chemistry and molecular modeling software and services for pharma R&D, comparable in providing physics-based computational tools to drug discovery teams.
Others
- OpenEye Scientific (Cadence): OpenEye provides molecular modeling and simulation software used in pharmaceutical drug discovery, supplying enabling technology and tooling that overlaps with HTuO's physics-based simulation capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
HTuO Biosciences social profiles
Digital presenceHTuO Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
HTuO Biosciences leadership team
Management profileNumber of profiles
Profiles5 records
HTuO Biosciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HTuO Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HTuO Biosciences
What does HTuO Biosciences do?
HTuO Biosciences develops and provides a proprietary physics-based simulation platform that models drug-molecule interactions at the atomic level to predict drug mechanisms and therapeutic potential. The platform is offered to pharmaceutical partners through collaborative drug discovery partnerships, enabling access to targets and modalities that conventional in-silico methods cannot address.
Is HTuO Biosciences a public or private company?
HTuO Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was HTuO Biosciences founded?
HTuO Biosciences was founded in 2023. It employs 11 to 50 people.
Where is HTuO Biosciences based?
HTuO Biosciences is headquartered in Vancouver, Canada, in the North America region.
Who are HTuO Biosciences's main competitors?
Direct peers on record are Schrödinger, Atomwise and XtalPi. Broad incumbents are Recursion Pharmaceuticals, Exscientia, Insitro and Isomorphic Labs. Emerging players are Cyclica and Cresset. OpenEye Scientific (Cadence) is listed as an others.
Does HTuO Biosciences have an API?
No public API is recorded for HTuO Biosciences.
What industry is HTuO Biosciences in?
HTuO Biosciences's product category is Computational Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.